RYZ101 (225Ac-DOTATATE) + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor-Expressing Extensive-Stage SCLC

Document Type

Conference Proceeding

Publication Date

10-2025

Publication Title

Journal of Thoracic Oncology

Abstract

RYZ101 (225Ac-DOTATATE) is a first-in-class, alpha-emitting radiopharmaceutical in development for the treatment of patients with somatostatin receptor-expressing (SSTR2+) solid tumors. Alpha particles (emitted by 225Ac) have a higher linear energy transfer (80-100 keV/μm) and shorter path length (40-100 μm) than beta particles, potentially allowing for improved cancer cell kill rates while limiting off-tumor toxicity. Here we describe preliminary safety data from a single-arm, open-label, phase 1b dose-escalation and dose-expansion trial of RYZ101 in combination with standard of care (SoC) therapy in patients with treatment-naïve SSTR2+ extensive-stage small-cell lung cancer (ES-SCLC; NCT05595460).

Volume

20

Issue

10, Suppl 1

First Page

S39

Comments

World Conference on Lung Cancer, Sept. 6-9, 2025, Barcelona, Spain

Last Page

S39

DOI

10.1016/j.jtho.2025.09.075

ISSN

1556-0864

Link to Full Text

Share

COinS